Why X4 Pharmaceuticals, Inc. (XFOR) is Surging in 2025

We recently published a list of Why These 15 Healthcare Stocks Are Surging in 2025. In this article, we are going to take a look at where X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) stands against other healthcare stocks that are surging in 2025.

After lagging behind the broader market in 2024, many healthcare stocks are making a comeback this year. Healthcare spending has been continuously soaring and is projected to do so in the coming years due to demographic tailwinds. The industry now accounts for a fifth of the U.S. economy, and it’s a good idea to have exposure to it.

Most executives now hold a favorable view of the industry’s prospects, a notable increase from 52% just a year ago. Moreover, it’s an industry that is more insulated from tariffs and macro risks.

Of course, the top gainers here are not defensive healthcare stocks, but it’s still worth looking into the winners here if you are chasing potential multibaggers.

Even during bear markets, there are pockets of the market that perform exceptionally well. For example, I identified 15 Energy Stocks that are Up the Most in 2025 in another article.

Methodology

For this article, I screened the best-performing healthcare stocks year-to-date.

I will also mention the number of hedge fund investors in these stocks. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR)

Number of Hedge Fund Holders In Q4 2024: 8

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) is a clinical-stage biopharmaceutical company developing novel therapies that improve immune cell trafficking, with a focus on rare diseases such as WHIM syndrome and chronic neutropenic disorders.

The stock is up significantly so far in 2025 as the company’s lead product, XOLREMDI (mavorixafor), is an oral CXCR4 antagonist that received U.S. approval in 2024 and is now being marketed for WHIM syndrome.

This marked X4 Pharmaceuticals, Inc. (NASDAQ:XFOR)’s transition to a fully integrated commercial company. The most impactful event for the stock in 2025 has been the continued commercial rollout of XOLREMDI, the initiation and expansion of the global Phase 3 4WARD trial for chronic neutropenia, and the anticipation of potential European approval.

On April 24, 2025, X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) announced a reverse stock split to address Nasdaq’s minimum bid price requirement, which is intended to stabilize and potentially boost the share price. The company reported $2.6 million in net revenues from XOLREMDI since its May 2024 launch and expects a significant ramp-up in 2025 as physician outreach increases. The stock has since experienced high volatility.

The consensus price target of $85 implies significant upside from the current price.

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) stock is up 676.99% year-to-date.

Overall, XFOR ranks 2nd on our list of healthcare stocks that are surging in 2025. While we acknowledge the potential of XFOR as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than XFOR but that trades at less than 5 times its earnings, check out our report about this cheapest AI stock.

READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.

Disclosure: None. This article is originally published at Insider Monkey.